European Regulators Validated Lorecivivint Application
The European Medicines Agency has formally accepted the marketing application for the knee osteoarthritis treatment.
Updated on Oct. 2, 2026 in Arthritis
Live Poll
Should new arthritis treatments focus more on structural joint improvement than on temporary pain relief?
The European Medicines Agency has validated the marketing authorization application for lorecivivint, a potential disease-modifying therapy for knee osteoarthritis. This milestone follows a similar validation by the United Kingdom's Medicines and Healthcare products Regulatory Agency in August.
Why it matters
The validation marks a crucial step in the regulatory review process for a therapy designed to treat knee osteoarthritis through joint injections. If approved, the treatment would offer a new medical approach for millions of adults suffering from the condition globally.
Lorecivivint is designed for injection into the knee joint 1-2 times per year to inhibit specific kinases. Currently, approximately 500 million adults globally live with some form of osteoarthritis.
The players
European Medicines Agency
This is the European Union agency responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
Medicines and Healthcare products Regulatory Agency
This is the executive agency of the United Kingdom government responsible for ensuring that medicines and medical devices work and are acceptably safe.
Biosplice Therapeutics
This company is the developer of lorecivivint and is headquartered in San Diego.
The details
Lorecivivint is a small-molecule inhibitor that functions by targeting DYRK1A and CLK2 kinases within the knee joint. The therapy aims to address structural damage, building on evidence from the Phase 3 OA-07 clinical trial which indicated improvements in medial joint space width.
Timeline
February 2026: The CHMP confirmed the drug's eligibility for the centralized review procedure.
August 28, 2026: The UK MHRA validated the marketing authorization application.
September 30, 2026: The European Medicines Agency validated the marketing authorization application.
The Big Picture
The progress of lorecivivint follows a long-standing framework established by the EMA guidelines for osteoarthritis structural damage endpoints. This development represents a significant attempt to satisfy these rigorous standards to achieve approval as a disease-modifying therapy.
The potential approval of this therapy would introduce a new treatment option for the 25 million U.S. adults currently living with knee osteoarthritis. Patients may eventually see changes to their long-term management routines if the drug reaches the market.
The takeaway
Lorecivivint aims to fill a significant gap in treatment for those suffering from the chronic pain and structural damage of knee osteoarthritis. Regulatory progress in Europe and the UK signals that researchers are moving closer to providing a targeted, injection-based solution.
Further reading
For more information on current treatment landscapes, visit the Arthritis section.
Source note: This article includes information reported by The Manila times.
Live Poll
Should new arthritis treatments focus more on structural joint improvement than on temporary pain relief?
